Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase
Paquet T., Le Manach C., Cabrera DG., Younis Y., Henrich PP., Abraham TS., Lee MCS., Basak R., Ghidelli-Disse S., Lafuente-Monasterio MJ., Bantscheff M., Ruecker A., Blagborough AM., Zakutansky SE., Zeeman A-M., White KL., Shackleford DM., Mannila J., Morizzi J., Scheurer C., Angulo-Barturen I., Martínez MS., Ferrer S., Sanz LM., Gamo FJ., Reader J., Botha M., Dechering KJ., Sauerwein RW., Tungtaeng A., Vanachayangkul P., Lim CS., Burrows J., Witty MJ., Marsh KC., Bodenreider C., Rochford R., Solapure SM., Jiménez-Díaz MB., Wittlin S., Charman SA., Donini C., Campo B., Birkholtz L-M., Hanson KK., Drewes G., Kocken CHM., Delves MJ., Leroy D., Fidock DA., Waterson D., Street LJ., Chibale K.
MMV390048, a member of a new class of inhibitors of the Plasmodium phosphatidylinositol 4-kinase, shows potential for both treatment and prophylaxis.